IL2 and neoplasm: To verify that IL-2/JES6 expands tumor-specific CD8+ T cells which are subsequently able to reject cancer, we used a model of MC38 colon carcinoma expressing OVA (MC38/OVA)32 growing in CD3ε−/− mice with adoptively transferred OT-I CD8+ T cells.